Stock Research for DVAX


Featured Broker: Ally Invest

Get the due diligence for another stock.


DVAX Stock Chart & Research Data

The DVAX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DVAX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


DVAX Due diligence Resources & Stock Charts

The DVAX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DVAX Detailed Price Forecast - CNN Money CNN View DVAX Detailed Summary - Google Finance
Yahoo View DVAX Detailed Summary - Yahoo! Finance Zacks View DVAX Stock Research & Analysis -

Stock Analysis

TradeIdeas View DVAX Trends & Analysis - Trade-Ideas Barrons View DVAX Major Holders - Barrons
NASDAQ View DVAX Call Transcripts - NASDAQ Seeking View DVAX Breaking News & Analysis - Seeking Alpha
Spotlight View DVAX Annual Report - OTC Report View DVAX OTC Short Report -
TradeKing View DVAX Fundamentals - TradeKing Charts View DVAX SEC Filings - Bar Chart
WSJ View Historical Prices for DVAX - The WSJ Morningstar View Performance/Total Return for DVAX - Morningstar
MarketWatch View the Analyst Estimates for DVAX - MarketWatch CNBC View the Earnings History for DVAX - CNBC
StockMarketWatch View the DVAX Earnings - StockMarketWatch MacroAxis View DVAX Buy or Sell Recommendations - MacroAxis
Bullish View the DVAX Bullish Patterns - American Bulls Short Pains View DVAX Short Pain Metrics -

Social Media Mentions

StockTwits View DVAX Stock Mentions - StockTwits PennyStocks View DVAX Stock Mentions - PennyStockTweets
Twitter View DVAX Stock Mentions - Twitter Invest Hub View DVAX Investment Forum News - Investor Hub
Yahoo View DVAX Stock Mentions - Yahoo! Message Board Seeking Alpha View DVAX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for DVAX - Insider Cow View Insider Transactions for DVAX - Insider Cow
CNBC View DVAX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DVAX - OTC Markets
Yahoo View Insider Transactions for DVAX - Yahoo! Finance NASDAQ View Institutional Holdings for DVAX - NASDAQ

Stock Charts

FinViz View DVAX Stock Insight & Charts - StockCharts View DVAX Investment Charts -
BarChart View DVAX Stock Overview & Charts - BarChart Trading View View DVAX User Generated Charts - Trading View

Latest Financial News for DVAX

Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Posted on Tuesday September 04, 2018

Dynavax Technologies Corporation (DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity. The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.Gallotta, H. Assi, E. Degagné, S. Kannan, R.Coffman and C. Guiducci was published in the journal Cancer Research.

Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Posted on Tuesday August 28, 2018

Dynavax Technologies Corporation (DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR). The investigators report clinical activity and broad immune activation in the tumor microenvironment when SD-101 is administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or metastatic melanoma. “Promising data from multiple trials studying intratumoral administration of TLR9 agonists indicate that stimulating the innate immune system through the TLR9 pathway can enhance the adaptive immune response to both injected and non-injected tumors,” said Antoni Ribas, M.D., Ph.D., Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.

Is Dynavax Technologies Corporation a Buy?
Posted on Sunday August 19, 2018

A slow launch for its hepatitis B vaccine has hurt Dynavax. But are better days ahead?

Edited Transcript of DVAX earnings conference call or presentation 6-Aug-18 8:30pm GMT
Posted on Friday August 17, 2018

Q2 2018 Dynavax Technologies Corp Earnings Call

Stock Market & Investing Books

Enter a stock symbol to view the stock details.